of this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURES Pursuant to the requir…

of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934…

Other Events. On March 2, 2026, the Company entered into an accelerated share repurchase agreement (the “ASR Agreement”) with JPMorgan Chase Bank, National Association (“JPMorgan”) to repurchase $125 million of shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), as part of the Company’s previously announced $500 million share repurchase program (the “Share Repurchase Program”), as disclosed on the Company’s Current Report on Form 8-K filed with the Securiti…

of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934…

Chief Financial Officer and Treasurer — Brad Tade: Mr. Tade is retiring from his position as Chief Financial Officer and Treasurer, with a successor named.

Results of Operations and Financial Condition. On January 12, 2026, ADMA Biologics, Inc. (the “Company”) issued a press release announcing the Company’s preliminary unaudited full year 2025 revenue and providing a business update. The results included in the press release are preliminary, have not been audited and are subject to change upon completion of the Company’s accounting and annual audit procedures and are, therefore, subject to adjustment. Additional information and disclosures are r…

of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant h…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. To the extent applicable, the disclosures of the material terms and conditions of the Credit Facilities included in

Entry into a Material Definitive Agreement On August 5, 2025 (the “Closing Date”), ADMA Biologics, Inc. (the “Company”), and all of the Company’s subsidiaries, entered into a Credit Agreement (the “Credit Agreement”), with the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the “Term Loan Facility”) an…

of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant h…

Termination of a Material Definitive Agreement To the extent applicable, the disclosures regarding the prepayment of the Ares Credit Facility included in

Other Events. Debt Reorganization On May 5, 2025, the Company borrowed $30.0 million under its revolving credit facility with Ares Capital Corporation (“Ares”), which the Company used to repay an additional $30.0 million against the Company’s term loan facility with Ares on May 6, 2025. Following such transactions, the Company has $72.5 million outstanding under its revolving credit facility and $2.5 million outstanding under its term loan facility. Share Repurchase Program On May 7, 2025, th…

of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant h…

Other Events. On April 28, 2025, ADMA Biologics, Inc., a Delaware corporation (the “Company”), issued a press release announcing that it has received U.S. Food and Drug Administration (“FDA”) approval of the Company’s innovative production yield enhancement process. This innovative process has demonstrated an ability to increase production yields by approximately 20% from the same starting plasma volume. A copy of the press release announcing the FDA approval is attached as Exhibit 99.1 to th…

of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant h…

CEO — Adam S. Grossman: The filing discloses the approval of annual executive compensation and equity awards, not a change in management personnel.

of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant h…

Director — Eduardo Rene Salas: The filing discloses the appointment of a new independent director to the Board, which is a standard governance action rather than a departure of a senior executive.

Other Events On December 20, 2024, ADMA Biologics, Inc. issued a press release announcing that it has repaid $30 million from its original $62.5 million senior secured term loan facility with Ares Capital Corporation and certain affiliated credit funds. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference herein.

Director — Bryant E. Fong: A long-serving director and Audit Committee Chairman resigned to focus on other roles, with immediate internal succession for key committee positions.

of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant…

Changes in Registrant’s Certifying Accountant. (b) Engagement of New Independent Registered Public Accounting Firm On October 31, 2024, ADMA Biologics, Inc. (the “Company”) and KPMG LLP (“KPMG”) executed an agreement pursuant to which KPMG will initiate its engagement and serve as the Company’s new independent registered public accounting firm effective upon the filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024. KPMG’s engagement will includ…

Changes in Registrant’s Certifying Accountant. (a) Resignation of Independent Registered Public Accounting Firm On October 3, 2024, the Audit Committee of the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) was informed by CohnReznick LLP (“CohnReznick”), the Company’s current independent registered public accounting firm, that CohnReznick will resign as the Company’s independent registered public accounting firm effective as of the filing of the Company’s Quarterly R…

Other Events On August 14, 2024, ADMA Biologics, Inc. issued a press release announcing that it has repaid $30 million from its original $72.5 million revolving credit facility with Ares Capital Corporation and certain affiliated credit funds. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference herein.

of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant…